Dendreon's CEO Exits: Is this the Beginning of the End?

Dendreon CEO John Johnson announced yesterday that he is stepping down for "personal reasons." His departure comes ahead of a large company debt payment. Could Dendreon be on the precipice of bankruptcy?

Jun 10, 2014 at 2:30PM

Dendreon (NASDAQ:DNDN) CEO and Chairman John Johnson has decided to call it quits after overseeing the biotechnology company's turbulent restructuring and attempted turnaround over the last two years. In 2012, Johnson took over for Mitchell Gold, who was unable to shepherd the company's prostate cancer vaccine Provenge to commercial success and following his departure became embroiled in an SEC investigation for insider trading. 

Although Johnson instituted deep layoffs and even sold one of Provenge's manufacturing facilities to Novartis, the drug's inability to compete against cheaper and easier to take rivals like Johnson & Johnson's (NYSE:JNJ) Zytiga have kept Dendreon operating in the red. The rapid market uptake of Medivation and Astellas Pharma's competing Xtandi looks like it could put even more downward pressure on Provenge sales.

Johnson's departure comes ahead of a $26.3 million debt payment that is due on June 15. As Dendreon reportedly has about $170 million in cash, it should be able to handle this payment, but the bigger concern is the $560 million in senior notes due in 2016.

With Provenge sales essentially flatlining in recent quarters and annual sales likely to stall out at roughly $320 million per year, there is good reason to believe Dendreon will face some tough choices come 2016. With that in mind, let's take a closer look at why Johnson's sudden departure might be an ominous sign of things to come.

Johnson has jumped ship before
Most Dendreon investors probably recall that Johnson accepted the CEO position after a tumultuous tenure at the now-defunct Savient Pharmaceuticals. Similar to Dendreon's current situation, Savient was having troubles selling its lead commercial product Krystexxa, a treatment for chronic gout.

Despite a rigorous education campaign spearheaded by Johnson, the company was unable to right its ship. As a result, Savient filed for bankruptcy protection in October 2013, roughly 14 months after Johnson's departure, and was eventually sold for a mere $120 million.  

Dendreon appears to be sinking
A quick look at the chart below pretty much sums up Johnson's tenure at Dendreon. Since he took the helm in July 2012, the company's share price has cratered a whopping 71%.  

DNDN Chart

DNDN data by YCharts.

Dendreon's sinking share price and deepening financial problems certainly aren't solely Johnson's fault --  the company was in trouble prior to his tenure. And he did oversee a massive cost-cutting effort that has shrunk the company's net loss by a notable 50% year over year. 

But now there doesn't appear to be much else to cut, and Provenge simply isn't generating top-line growth for the company. With Exelixis potentially entering the prostate cancer arena next year with cabozantinib, Provenge sales may be on a downward spiral at a time when the company desperately needs revenue growth. 

Foolish wrap-up
I think the CEO's departure at this critical time bodes poorly for Dendreon. Absent a dramatic turnaround, the company is likely to be sold piecemeal to the highest bidders following a bankruptcy filing. It's no secret that Dendreon tried to sell itself last year, but that process has apparently reached a dead end.

My view is that potential buyers likely see the company as a dead man walking and will simply wait for the bankruptcy procedures to start in order to get the lowest possible price for the pieces they desire. In other words, it looks like the Savient situation all over again. 

Will this stock be your next multibagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.



George Budwell owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers